Bone Marrow Aspirate Concentrate: BMAC Definition — 1 Key Difference From Allogeneic Stem Cells

Bone marrow aspirate concentrate is an autologous biologic prepared by aspirating bone marrow from the patient's own iliac crest or other accessible site, then centrifuging the aspirate to concentrate the mononuclear cell fraction containing mesenchymal stem cells, hematopoietic progenitor cells, and growth factors.

What Bone Marrow Aspirate Concentrate Is

Bone marrow aspirate concentrate (BMAC) is a point-of-care biologic produced from the patient's own body. A needle is inserted into the posterior iliac crest (pelvis) under local anesthesia, and a volume of bone marrow aspirate (typically 60 to 120 mL) is collected. The aspirate is centrifuged to separate red blood cells from the nucleated cell fraction. The concentrated cellular preparation (BMAC) is then injected at the treatment site, typically on the same day.

BMAC contains MSCs, hematopoietic stem cells (HSCs), platelets, and growth factors. The concentration of MSCs in BMAC is variable and depends on the patient's age, bone marrow health, and the aspiration and processing technique.

How BMAC Compares to Allogeneic Umbilical Cord Stem Cells

The key clinical difference between BMAC and allogeneic umbilical cord-derived stem cells (such as DayZero™) is cell age and paracrine output. BMAC cells are autologous, from the patient's own body, which eliminates donor-related immune considerations. However, the patient's own MSCs are subject to age-related cellular senescence: a 60-year-old patient's MSCs produce a less potent paracrine signal than the young perinatal MSCs in DayZero™ products.

In practical clinical terms, allogeneic umbilical cord MSCs from a young, documented donor source often produce a more robust regenerative signal than BMAC in an older patient. The trade-off is that BMAC is fully autologous (no donor biology) while DayZero™ is allogeneic (donor-sourced, physician-supervised, SB 1768 compliance required).

How Rebuild Regen Approaches BMAC vs. Allogeneic Stem Cells

Rebuild Regen Medical Clinic at 3320 N Federal Hwy #101, Lighthouse Point, FL primarily uses DayZero™ umbilical cord stem cells. The clinical rationale is the documented quality and paracrine output advantage of young donor-source MSCs over autologous bone marrow in the patient population we serve. BMAC remains a clinical option discussed during the consultation when autologous sourcing is the patient's preference.

All stem cell protocols require supervision by Dr. Cedric Emden Davis II, MD under Florida SB 1768.

Is BMAC the Right Option for Your Situation?

BMAC is appropriate for patients who prefer a fully autologous procedure and whose bone marrow cellularity supports a clinically useful MSC yield. It is less appropriate in older patients (over 55 to 60) where MSC senescence limits the paracrine output, or in patients where the aspiration procedure itself carries meaningful risk.

Risks and Limitations of BMAC

Bone marrow aspiration carries procedural risks including pain, infection, bleeding at the aspiration site, and, rarely, nerve injury. The concentration and viability of MSCs in BMAC is variable and cannot be verified to the same standard as a COA-documented allogeneic product. In patients with compromised bone marrow health (prior chemotherapy, hematologic conditions), BMAC yield may be clinically insufficient.